Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 3
1998 3
1999 3
2000 3
2001 3
2002 2
2003 3
2004 3
2005 7
2006 16
2007 17
2008 14
2009 11
2010 11
2011 11
2012 13
2013 7
2014 10
2015 10
2016 6
2017 10
2018 10
2019 8
2020 10
2021 15
2022 9
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

206 results
Results by year
Filters applied: . Clear all
Page 1
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. Wingerchuk DM, et al. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19. Neurology. 2015. PMID: 26092914 Free PMC article.
Neuromyelitis Spectrum Disorders.
Weinshenker BG, Wingerchuk DM. Weinshenker BG, et al. Among authors: wingerchuk dm. Mayo Clin Proc. 2017 Apr;92(4):663-679. doi: 10.1016/j.mayocp.2016.12.014. Mayo Clin Proc. 2017. PMID: 28385199 Review.
The spectrum of neuromyelitis optica.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. Wingerchuk DM, et al. Lancet Neurol. 2007 Sep;6(9):805-15. doi: 10.1016/S1474-4422(07)70216-8. Lancet Neurol. 2007. PMID: 17706564 Review.
Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM, Lucchinetti CF. Wingerchuk DM, et al. N Engl J Med. 2022 Aug 18;387(7):631-639. doi: 10.1056/NEJMra1904655. N Engl J Med. 2022. PMID: 36070711 Review. No abstract available.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: wingerchuk dm. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM. Pittock SJ, et al. Among authors: wingerchuk dm. N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3. N Engl J Med. 2019. PMID: 31050279 Clinical Trial.
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Armstrong R, Wingerchuk DM; PREVENT Study Group. Pittock SJ, et al. Among authors: wingerchuk dm. Mult Scler. 2022 Mar;28(3):480-486. doi: 10.1177/13524585211038291. Epub 2021 Sep 9. Mult Scler. 2022. PMID: 34498507 Free PMC article. Clinical Trial.
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide.
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K. Hor JY, et al. Among authors: wingerchuk dm. Front Neurol. 2020 Jun 26;11:501. doi: 10.3389/fneur.2020.00501. eCollection 2020. Front Neurol. 2020. PMID: 32670177 Free PMC article. Review.
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Wingerchuk DM, et al. Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27. Ann Neurol. 2021. PMID: 33586143 Free PMC article. Clinical Trial.
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Chen JJ, et al. Among authors: wingerchuk dm. Neurology. 2020 Jul 14;95(2):e111-e120. doi: 10.1212/WNL.0000000000009758. Epub 2020 Jun 17. Neurology. 2020. PMID: 32554760 Free PMC article.
206 results